Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Allogene TherapeuticsALLO -5.99%32 EV-to-OCF is -4.33 as of Aug. 26, 2026. GuruFocus rates ALLO with a GF Score™ of 32/100. The stock has 4 warning signs investors should review. Among 1,409 Biotechnology companies, Allogene Therapeutics ranks better than 55.07% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Allogene Therapeutics's Enterprise Value is $442.55 Mil.
Allogene Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was $-102.20 Mil. Therefore, Allogene Therapeutics's EV-to-OCF for today is -4.33.
The historical rank and industry rank for Allogene Therapeutics's EV-to-OCF or its related term are showing as below:
ALLO'
s EV-to-OCF Range Over the Past 10 Years
Min: -32.11 Med: -1.04 Max: 1.01
Current: -4.33
During the past 9 years, the highest EV-to-OCF of Allogene Therapeutics was 1.01. The lowest was -32.11. And the median was -1.04.
ALLO's EV-to-OCF is ranked better than 55.07% of 1409
companies
in the Biotechnology industry
Industry Median: -3.71
vs ALLO: -4.33
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Allogene Therapeutics's PE Ratio (TTM) for today is calculated as:
Allogene Therapeutics's share price for today is $2.04.
Allogene Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.670.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Allogene Therapeutics's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Allogene Therapeutics EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Allogene Therapeutics's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Allogene Therapeutics's EV-to-OCF falls into.
Allogene Therapeutics's current Enterprise Value is $442.55 Mil.
Allogene Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-102.20 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Allogene Therapeutics (ALLO) has a EV-to-OCF of -4.33 as of Aug. 26, 2026. According to the industry distribution chart, Allogene Therapeutics ranks #633 out of 1409 companies in the Biotechnology industry, placing it in the top 44.9%.
Is Allogene Therapeutics' EV-to-OCF too high?
Allogene Therapeutics' current EV-to-OCF is -4.33. Based on the distribution chart, Allogene Therapeutics ranks #633 out of 1409 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Allogene Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Allogene Therapeutics' EV-to-OCF compare to CBIO and IMMX?
According to the Biotechnology industry distribution chart, Allogene Therapeutics ranks #633 out of 1409 companies for EV-to-OCF. This puts Allogene Therapeutics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Allogene Therapeutics's current EV-to-OCF is -4.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Allogene Therapeutics stock overvalued right now?
Allogene Therapeutics (ALLO) has a current EV-to-OCF of -4.33. The current EV-to-OCF is -4.33. Allogene Therapeutics' overall GF Score™ is 32/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Allogene Therapeutics (ALLO), the current EV-to-OCF is -4.33 as of Aug. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).
32GF Score
Get the complete analysis for ALLO
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ALLO has been successfully added to your 
